Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: A single-centre study of 20 patients

Annals of Hematology

Volumn 86, Issue 4, 2007, Pages 271-276

  Aydin, Semra ^a   Dührsen, Ulrich ^a   Nückel, Holger ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Anti CD20 antibody rituximab; ASHAP; Non Hodgkin's lymphoma; Relapse; Salvage chemotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIHISTAMINIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHYLPREDNISOLONE; PARACETAMOL; PREDNISONE; RITUXIMAB; STEROID; VINCRISTINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART DISEASE; HEART EJECTION FRACTION; HUMAN; INFECTION; KIDNEY DISEASE; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE HYPOTONIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; SEPSIS; SIDE EFFECT; THROAT DISEASE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYTARABINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; METHYLPREDNISOLONE; METHYLPREDNISOLONE HEMISUCCINATE; MIDDLE AGED; NAUSEA; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 33847648833     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-006-0243-9     Document Type: Article

References (19)

1. Philip T, Guglielmi C, Hagenbeek A et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545
2. Philip T, Armitage JO, Spitzer G et al (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316:1493-1498
3. Press OW, Livingston R, Mortimer J, Collins C, Appelbaum F (1991) Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 9:423-431
4. Velasquez WS, Cabanillas F, Salvador P et al (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71:117-122
5. Nückel H, Dürig J, Dührsen U (2003) Salvage chemotherapy according to the ASHAP protocol: A single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin's lymphomas. Ann Hematol 82:481-486
6. Hänel M, Kröger N, Hoffknecht MM et al (2000) ASHAP - an effective salvage therapy for recurrent and refractory malignant lymphomas. Ann Hematol 79:304-311
7. Velasquez W, Dunphy F, Petruska PJ, Adkins D, Broun GO Jr, Spitzer G (1995) ASHAP with or without ABMT for high risk non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 14:387 (Abstr 1205)
8. Velasquez W, Dunphy F, Santillana S, Adkins D, Browers C, Broun GO Jr, Petruska PJ, Spitzer G (1993) ASHAP, an effective treatment for relapsing and refractory Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). Blood 82(Suppl 1):138a (Abstr 538)
9. Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242
10. Coiffier B, Haioun C, Ketterer N et al (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932
11. Tobinai K, Igarashi T, Itoh K et al (2004) Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 15:821-830
12. Rothe A, Schulz H, Elter T, Engert A, Reiser M (2004) Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma. Haematologica 89:875-876
13. Kewalramani T, Zelenetz AD, Nimer SD et al (2004) Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103:3684-3688
14. Venugopal P, Gretory S, Showel J et al (2004) Rituximab (Rituxan) combined with ESHAP chemotherapy is highly active in relapsed/refractory aggressive non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 104:4636, (Abstract)
15. Hicks L, Buckstein R, Piliotis E et al (2004) Rituximab+ESHAP as salvage chemotherapy for relapsed/refractory aggressive non-Hodgkins lymphoma: A phase II trial. Blood (ASH Annual Meeting Abstracts) 104:5230, (Abstract)
16. Mey U, Strehl J, Orlopp KS et al (2004) A phase II trial of dexamethasone, high-dose cytarabine, and cisplatin (DHAP) in combination with rituximab as salvage treatment for patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 104:4618, (Abstract)
17. Rupolo M, Spina M, Michieli M et al (2004) R-DHAOX as salvage regimen in patients (pts) with relapsed/resistant non-Hodgkins lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 104:1323, (Abstract)
18. Wenger C, Stern M, Herrmann R, Rochlitz C, Pless M (2005) Rituximab plus gemcitabine: A therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma? Leuk Lymphoma 46:71-75
19. Gnaoui T, Dupuis J, Joly B et al (2004) Rituximab, gemcitabine and oxaliplatin (R-GEMOX): A promising regimen for refractory/relapsed B-cell lymphoma. Blood (ASH Annual Meeting Abstracts) 104:2483, (Abstract)